Optimi Health Reports Q3 Loss, Confirms 12-Month Cash Runway
OPTH sits 50% above its 52-week low of $3.12 on light trading volume (0.2× avg).
Summary
Optimi Health filed its Q3 FY2026 financials, reporting a $5.7 million net loss but confirming a 12-month cash runway with $13.1 million in cash.
Key Events · Earnings and Guidance · OPTH
-
Q3 FY2026 Financial Results
Revenue of $239,700 and net loss of $5,715,536 for the nine months ended June 30, 2026, compared to revenue of $490,330 and net loss of $2,362,664 in the prior-year period.
-
Going Concern Resolved
Management concluded the company has sufficient cash resources and expected cash flows to continue operations for at least twelve months, with $13,073,333 in cash as of June 30, 2026.
-
Debt Reduction
Repaid $1,000,000 in loans during the period and an additional $1,000,000 subsequent to June 30, 2026; settled $450,000 in convertible debt through issuance of 100,000 common shares.
-
Nasdaq Listing Costs
Investor relations expense of $1,166,558 and consulting of $940,620 were incurred primarily in connection with the Nasdaq listing and U.S. public offering, contributing to the wider loss.
Analysis · OPTH · Life Sciences
Optimi Health's Q3 FY2026 results show a net loss of $5.7 million on revenue of $239,700, but the company holds $13.1 million in cash and management has concluded it has sufficient resources for at least twelve months. This removes the near-term going concern risk that had been a major overhang on the stock. The loss was driven by heavy spending on investor relations and consulting tied to the Nasdaq listing, which is now complete.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1012 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPTH was trading at $4.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.4M. The 52-week trading range was $3.12 to $8.84. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.